In the absorption section, olaparib is predicted as P-glycoprotein (Pgp) substrate and inhibitor with high possibility, which is consistent with the publication demonstrating that increased Pgp drug efflux transporter expression enables an intrinsic resistance of olaparib in metaplastic breast carcinoma (43). This evidence concerns the gene PGP and metaplastic breast carcinoma.